This is a transformative pipeline catalyst for Ionis. The 19% functional cure rate vs <1% standard of care positions bepirovirsen as a potential blockbuster in a 240M+ patient market. Monitor FDA decision in Q3 2026 and GSK's launch preparations. The royalty stream could meaningfully impact Ionis revenue starting 2027.
Price Chart
Executive Summary
Ionis partner GSK reported positive Phase 3 data for bepirovirsen in chronic hepatitis B, showing a 19% functional cure rate vs 0% for standard of care. The drug is under priority FDA review with decisions expected in Q3 2026, and Ionis is eligible for tiered royalties of 10-12% on net sales plus milestones.
Key Facts
- Bepirovirsen achieved 19% functional cure rate (233/1,220) vs 0% placebo in pooled Phase 3 B-Well 1 & 2 trials (p<0.001)
- In patients with baseline HBsAg ≤1000 IU/mL, functional cure rate was 26% (200/768) vs 0% placebo
- Current standard of care achieves functional cure in <1% of patients
- FDA priority review with Breakthrough and Fast Track Designation; first regulatory decisions expected Q3 2026
- Ionis receives tiered royalties of 10-12% on net sales of bepirovirsen plus milestone payments
- Results published in NEJM and presented at EASL congress
Financial Impact
Ionis eligible for tiered royalties of 10-12% on net sales plus additional regulatory and sales milestone payments; no specific dollar amounts disclosed
Risk Factors
- FDA or other regulatory agencies could reject or delay approval
- Commercial adoption may be slower than expected despite strong efficacy data
- Competing hepatitis B therapies in development could limit market share
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-023093 |
| Document: ef20075060_ex99-1.htm | 0001140361-26-023093 |
| Document: 0001140361-26-023093-index-headers.html | 0001140361-26-023093 |
| Document: 0001140361-26-023093-index.html | 0001140361-26-023093 |
| Document: 0001140361-26-023093.txt | 0001140361-26-023093 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $42.93 | awaiting T+20 | — | $43.96 (+2.40%) |
Oct 21, 2026 5d ago | 8-K | $43.91 | awaiting T+20 | — | $43.96 (+0.11%) |
Oct 21, 2026 6d ago | Institutional Cluster | $43.91 | awaiting T+20 | — | $43.96 (+0.11%) |
Sep 23, 2026 4w ago | 8-K | $43.93 $44.27 | ▲ +0.77% | ▲ +0.09% | $43.96 (+0.07%) |
Sep 4, 2026 7w ago | 8-K | $56.71 $44.00 | ▲ +22.41% | ▲ +24.13% | $43.96 (+22.48%) |
Sep 4, 2026 7w ago | 8-K | $58.09 $43.50 | ▼ −25.12% | ▼ −25.72% | $43.96 (−24.32%) |
Jul 31, 2026 12w ago | Insider Buy | $54.49 $60.36 | ▲ +10.77% | ▲ +9.53% | $43.96 (−19.32%) |
Jul 29, 2026 12w ago | 8-K | $54.04 $63.36 | ▲ +17.25% | ▲ +12.23% | $43.96 (−18.65%) |
Jul 9, 2026 15w ago | 8-K | $58.25 $56.56 | ▼ −2.90% | ▼ −5.33% | $43.96 (−24.53%) |
Jul 9, 2026 15w ago | Insider Cluster | $58.25 $56.56 | ▼ −2.90% | ▼ −5.33% | $43.96 (−24.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers